Transcription factors Xbp-1, Blimp-1, and BSAP are involved in the regulation of plasmacytic differentiation induced by 2-methoxyestradiol in myeloma cell lines

被引:1
作者
Hua Jiang
WeiRan Gao
Daniel Man-Yuen Sze
Hong Xiong
Jian Hou
机构
[1] Changzheng Hospital,Department of Hematology
[2] The University of Sydney,Cancer Immunology Group, Faculty of Pharmacy
关键词
Xbp-1; Blimp-1; 2-Methoxyestradiol; Cell differentiation; Multiple myeloma;
D O I
10.1007/BF02984001
中图分类号
学科分类号
摘要
Our previous studies demonstrated that a low concentration of 2-methoxyestradiol (2ME2) could induce the differentiation of myeloma cell lines and CD138+ primary myeloma cells from myeloma patients and up-regulate the expression of messenger RNA (mRNA) and protein for the gene encoding X-box binding protein 1 (Xbp-1) in myeloma cell lines. In the present study, we used phosphorothioated antisense oligodeoxynucleotides (ASODN) to investigate the roles and interactions of transcription factors Xbp-1, B-lymphocyte induced maturation protein 1 (Blimp-1), and PAX-5-encoded B-cell-specific activator protein (BSAP), which are thought to be involved in the regulation of B-lymphocytic or plasmacytic differentiation. Blimp-1 ASODN and Xbp-1 ASODN clearly inhibited myeloma cell differentiation and significantly partially inhibited the differentiation effects induced by 2ME2 at low concentration, whereasPAX- 5 ASODN clearly induced myeloma cell differentiation and significantly enhanced 2ME2-induced differentiation effects. Moreover, after incubation with Blimp-1 ASODN, the level of Xbp-1 mRNA clearly declined, whereas the level ofPAX- 5 mRNA significantly increased in myeloma cells. These results demonstrate that transcription factors Xbp-1, Blimp-1, andPAX-5-encoded BSAP play important roles in the regulation of plasmacytic differentiation and exert their effects on differentiation induced by low 2ME2 concentrations. Our primary study provided the rationale for a promising strategy—the future application of transcription-factor ASODN for clinical patients.
引用
收藏
页码:429 / 437
页数:8
相关论文
共 84 条
[1]  
Sze DM(2000)Intrinsic constraint on plasmablast growth and extrinsic limits of plasma cell survival J Exp Med. 192 813-821
[2]  
Toellner KM(2000)2-Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate Cancer Metastasis Rev. 19 173-179
[3]  
Garcia de Vinuesa C(2003)Superoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cells Oncogene 22 6296-6300
[4]  
Taylor DR(2003)Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays Blood. 101 3606-3614
[5]  
MacLennan IC(2004)Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of bortezomib/proteasome inhibitor PS-341 Oncogene 23 3597-3602
[6]  
Pribluda VS(1995)Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicine binding site J Med Chem. 38 2041-2049
[7]  
Gubish ER(1994)2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site Proc Natl Acad Sci USA. 91 3964-3968
[8]  
La Vallee TM(2000)SULT1A1 catalyzes 2-methoxyestradiol sulfonation in MCF-7 breast cancer cells Carcinogenesis 21 1947-1957
[9]  
Treston A(2000)Superoxide dismutase as a target for the selective killing of cancer cells Nature 407 390-395
[10]  
Swartz GM(2005)2-Methoxyestradiol at low dose induces differentiation of myeloma cells Leuk Res. 29 1059-1067